Evolent Health (NYSE:EVH) Posts Earnings Results, Beats Estimates By $0.03 EPS

Evolent Health (NYSE:EVH) issued its quarterly earnings data on Thursday. The technology company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.03, FiscalAI reports. The firm had revenue of $496.25 million during the quarter, compared to analysts’ expectations of $534.00 million. Evolent Health had a negative net margin of 26.29% and a positive return on equity of 0.32%. The business’s revenue was up 2.6% on a year-over-year basis. During the same period last year, the company earned $0.06 earnings per share.

Here are the key takeaways from Evolent Health’s conference call:

• Reported solid Q1 results with $496M revenue (9% sequential ex?ECP), adjusted EBITDA of $22M, and management reiterated full?year guidance of $2.4B–$2.6B revenue and $110M–$140M adjusted EBITDA with an estimated MER of ~93%.
• Performance Suite momentum: launches with Aetna and Highmark plus two new deals — an advanced imaging contract covering 4.5M lives and a Performance Suite oncology/cardiology expansion expected to generate over $200M annual revenue — validating cross?sell and scale potential.
• Oncology remains a strategic growth engine: Evolent manages ~10% of the oncology market today, sees meaningful outsourcings ahead, and is using Enhanced Performance Suite structures to offer guarantees while reducing direct risk exposure.
• AI and automation progress: leadership hires and accelerated model deployment (imaging auto?approval lifts in the high teens to ~30%) support a target of auto?approving ~80% of authorization volume to reduce costs and improve provider experience.
• Near?term headwinds from exchange membership declines (guidance assumes ~40% drop) pressured Specialty T&S revenue and elevated servicing costs during grace periods; company ended Q1 with $142M unrestricted cash and $792M net debt.

Evolent Health Stock Performance

EVH stock traded down $0.08 during mid-day trading on Friday, hitting $4.19. The company had a trading volume of 2,959,838 shares, compared to its average volume of 2,597,587. The firm has a market cap of $468.22 million, a PE ratio of -0.88 and a beta of 0.83. The company has a debt-to-equity ratio of 2.34, a quick ratio of 1.31 and a current ratio of 1.31. Evolent Health has a 12 month low of $2.10 and a 12 month high of $12.06. The stock’s fifty day moving average price is $2.93 and its two-hundred day moving average price is $3.80.

Institutional Trading of Evolent Health

Hedge funds have recently added to or reduced their stakes in the stock. CIBC Private Wealth Group LLC raised its position in Evolent Health by 4,000.0% in the third quarter. CIBC Private Wealth Group LLC now owns 4,100 shares of the technology company’s stock worth $35,000 after acquiring an additional 4,000 shares during the period. Strs Ohio bought a new stake in Evolent Health in the first quarter worth about $47,000. Vise Technologies Inc. bought a new stake in Evolent Health in the fourth quarter worth about $50,000. Headlands Technologies LLC bought a new stake in Evolent Health in the second quarter worth about $58,000. Finally, RPO LLC bought a new stake in Evolent Health in the fourth quarter worth about $71,000.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on EVH. Oppenheimer reduced their price objective on shares of Evolent Health from $12.00 to $6.00 and set an “outperform” rating for the company in a report on Monday, March 2nd. Citigroup dropped their price target on shares of Evolent Health from $6.00 to $4.00 and set a “buy” rating on the stock in a research report on Thursday, February 26th. Royal Bank Of Canada dropped their price target on shares of Evolent Health from $5.00 to $3.00 and set a “sector perform” rating on the stock in a research report on Wednesday, February 25th. UBS Group dropped their price target on shares of Evolent Health from $10.00 to $5.00 and set a “buy” rating on the stock in a research report on Thursday, February 26th. Finally, BMO Capital Markets reissued an “outperform” rating and set a $3.50 price target on shares of Evolent Health in a research report on Wednesday, February 25th. Thirteen research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $6.12.

More Evolent Health News

Here are the key news stories impacting Evolent Health this week:

• Positive Sentiment: Evolent’s Q1 EPS loss of $0.02 was better than the expected loss of $0.05, suggesting profitability trends were slightly better than analysts feared. Evolent Health Q1 2026 Earnings Call Transcript
• Positive Sentiment: Needham raised its price target on EVH from $4.00 to $5.00 and reiterated a buy rating, pointing to additional upside from current levels. Needham Price Target Raise
• Positive Sentiment: The company also lifted full-year 2026 revenue guidance to a range of $2.4 billion to $2.6 billion, which signals management expects stronger business performance ahead. Evolent Announces First Quarter 2026 Results
• Neutral Sentiment: Revenue of $496.25 million missed Wall Street’s $534.0 million estimate, so investors are weighing the top-line shortfall against better-than-expected earnings and upbeat guidance. Evolent Health Misses Q1 Revenue Estimates

Evolent Health Company Profile

Evolent Health, Inc is a U.S.-based healthcare technology and services company that partners with health systems, physician organizations and health plans to design, build and operate value-based care programs. Headquartered in Arlington, Virginia, the company was founded in 2011 as a joint venture between TPG and the University of Pittsburgh Medical Center (UPMC). Evolent Health aims to help its clients transition from fee-for-service payment models to value-based care arrangements by leveraging its proprietary technology platforms and clinical expertise.

The company’s core offerings include care management solutions, population health analytics and clinical advisory services.